Staff working under French microbiologist Didier Raoult, who last year attracted worldwide attention, and notably from Donald Trump, with his claims that the anti-malaria drug hydroxychloroquine was an effective medication for the prevention and treatment of Covid-19, have accused him of falsifying biological test results to support his assertions. Pascale Pascariello reports.
As the Covid-19 pandemic continues its devastating path across the world, wreaking close to 200,000 recorded deaths from the virus and a global economic meltdown, the only evident hopes for a stabilised return to normal activity lies in a vaccine or a drug treatment to contain its spread. But few believe a vaccine will be realistically ready before, at the earliest, 2021. French microbiologist Didier Raoult has championed an immediately available antiviral compound called chloriquine, previously used against malaria, as a miracle drug that neutralises the virus, receiving the support of US President Donald Trump and last week hosting a visit to his laboratory by French President Emmanuel Macron. But as Pascale Pascariello reports, deep controversy surrounds the work of Raoult, a maverick amid France’s scientific establishment.
In China and the United States, as well as France, the drug chloroquine is one of the main focal points in the race to provide an effective treatment for the Covid-19 coronavirus. So far there is still insufficient data to show whether this anti-malaria drug will prove useful in treating people infected with the virus. And a French study praising its benefits has become mired in controversy. Rouguyata Sall reports.
Directeur de la publication : Edwy Plenel
Direction éditoriale : Stéphane Alliès et Carine Fouteau
Le journal MEDIAPART est édité par la Société Editrice de Mediapart (SAS).
Durée de la société : quatre-vingt-dix-neuf ans à compter du 24 octobre 2007.
Actionnaires directs et indirects : Société pour l’Indépendance de Mediapart, Fonds pour une Presse Libre, Association pour le droit de savoir
Rédaction et administration : 127 avenue Ledru-Rollin, 75011 Paris
Courriel : contact@mediapart.fr
Téléphone : + 33 (0) 1 44 68 99 08
Propriétaire, éditeur, imprimeur : Société Editrice de Mediapart
Abonnement : pour toute information, question ou conseil, le service abonnés de Mediapart peut être contacté par courriel à l’adresse : serviceabonnement@mediapart.fr ou par courrier à l'adresse : Service abonnés Mediapart, 11 place Charles de Gaulle 86000 Poitiers. Vous pouvez également adresser vos courriers à Société Editrice de Mediapart, 127 avenue Ledru-Rollin, 75011 Paris.
